UBS Group
CPHI icon

UBS Group’s China Pharma Holdings CPHI Stock Holding History

UBS Group’s Portfolio CPHI Stock Details CPHI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05K Buy
3,109
+2,720
+699% +$1.9K ﹤0.01% 9415
2026
Q1 		$237 Sell
389
-124
-24% -$104 ﹤0.01% 10010
2025
Q4 		$621 Sell
513
-18,678
-97% -$30.7K ﹤0.01% 9871
2025
Q3 		$37.4K Sell
19,191
-52,042
-73% -$88.4K ﹤0.01% 7761
2025
Q2 		$128K Buy
71,233
+60,785
+582% +$112K ﹤0.01% 7031
2025
Q1 		$27.5K Buy
10,448
+7,297
+232% +$16.7K ﹤0.01% 8009
2024
Q4 		$7.34K Buy
+3,151
New +$6.82K ﹤0.01% 8481
2024
Q2 		– Sell
-734
Closed -$2.72K – 9593
2024
Q1 		$2.72K Buy
734
+48
+7% +$211 ﹤0.01% 7842
2023
Q4 		$4.15K Buy
+686
New +$3.85K ﹤0.01% 7897
2023
Q1 		– Sell
-152
Closed -$7.58K – 9692
2022
Q4 		$7.58K Buy
+152
New +$9.27K ﹤0.01% 8884
2022
Q3 		– Sell
-25
Closed -$3K – 10412
2022
Q2 		$3K Buy
25
+6
+32% +$803 ﹤0.01% 9290
2022
Q1 		$4K Buy
+19
New +$3.97K ﹤0.01% 9279
2021
Q4 		– Sell
-39
Closed -$11K – 10307
2021
Q3 		$11K Buy
39
+8
+26% +$2.84K ﹤0.01% 7869
2021
Q2 		$11K Buy
+31
New +$11.1K ﹤0.01% 7959
2021
Q1 		– Sell
-38
Closed -$8K – 9041
2020
Q4 		$8K Sell
38
-58
-60% -$12.5K ﹤0.01% 7613
2020
Q3 		$18K Buy
96
+80
+500% +$18.5K ﹤0.01% 6380
2020
Q2 		$5K Sell
16
-96
-86% -$23.7K ﹤0.01% 7364
2020
Q1 		$28K Buy
112
+30
+37% +$7.9K ﹤0.01% 6262
2019
Q4 		$10K Buy
82
+73
+811% +$9K ﹤0.01% 7278
2019
Q3 		$1K Sell
9
-33
-79% -$4.51K ﹤0.01% 7821
2019
Q2 		$7K Buy
42
+36
+600% +$5.78K ﹤0.01% 7231
2019
Q1 		$1K Sell
6
-25
-81% -$3.68K ﹤0.01% 7525
2018
Q4 		$4K Buy
+31
New +$4.51K ﹤0.01% 7618
2018
Q3 		– Sell
-18
Closed -$2K – 8007
2018
Q2 		$2K Sell
18
-21
-54% -$2.83K ﹤0.01% 7720
2018
Q1 		$6K Sell
39
-55
-59% -$9.83K ﹤0.01% 7134
2017
Q4 		$8K Buy
+94
New +$8.16K ﹤0.01% 7147
2017
Q3 		– Sell
-27
Closed -$3K – 7745
2017
Q2 		$3K Buy
27
+18
+200% +$2.04K ﹤0.01% 7283
2017
Q1 		$1K Buy
+9
New +$1.14K ﹤0.01% 7412
2016
Q4 		– Sell
-16
Closed -$1.7K – 7793
2016
Q3 		$2K Buy
+16
New +$2.05K ﹤0.01% 7395
2016
Q2 		– Sell
-59
Closed -$5K – 7751
2016
Q1 		$5K Buy
59
+40
+211% +$3.01K ﹤0.01% 6994
2015
Q4 		$2K Buy
19
+4
+27% +$387 ﹤0.01% 7999
2015
Q3 		$1K Buy
+15
New +$1.82K ﹤0.01% 8203
2015
Q1 		– Sell
-11
Closed -$2K – 8889
2014
Q4 		$2K Buy
+11
New +$1.62K ﹤0.01% 9385

Other funds holding CPHI

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

UBS Group's CPHI Position: Q2 2026 in Review

UBS Group increased its China Pharma Holdings (CPHI) stake by 699% in Q2 2026, buying an estimated $1.9K and bringing the position to 3,109 shares worth $2.05K. The position accounts for ﹤0.01% of the portfolio, ranked #9415.

UBS Group first reported a position in CPHI in Q4 2014 and has held it in 33 quarters since. The position peaked at $128K in Q2 2025. 8 funds tracked by Wall St. Rank hold CPHI as of Q2 2026.

  • UBS Group held 3,109 shares of China Pharma Holdings worth $2.05K as of Q2 2026.
  • UBS Group bought 2,720 China Pharma Holdings shares in Q2 2026, an estimated $1.9K.
  • China Pharma Holdings made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9415 holding.
  • UBS Group first reported a position in China Pharma Holdings in Q4 2014 and has held it in 33 quarters since.
  • UBS Group's China Pharma Holdings position peaked at $128K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held China Pharma Holdings as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.